心脏输出引导的血流动力学治疗用于重大胃肠手术患者:OPTIMISE II 随机临床试验
这项多中心随机对照试验纳入2498例≥65岁、ASA II级及以上、接受择期重大胃肠手术的成人,比较术中及术后4小时微创心脏输出引导的静脉液体治疗联合低剂量正性肌力药与常规护理。主要终点术后30天感染在干预组289/1247(23.2%)与常规组283/1247(22.7%)之间无差异(调整OR 1.03,95%CI 0.84-1.25;P=0.81)。24小时内急性心脏事件干预组38/1250(3.0%)高于常规组21/1247(1.7%)(调整OR 1.82,95%CI 1.06-3.13;P=0.03),主要归因于心律失常增加。作者结论认为该干预未减少术后感染,与24小时内急性心脏事件增加相关,不推荐在未经选择患者中常规使用。
要点
- 主要终点术后30天感染:干预组23.2%(289/1247)vs 常规组22.7%(283/1247),调整OR 1.03(95%CI 0.84-1.25),P=0.81。
- 24小时内急性心脏事件:干预组3.0%(38/1250)vs 常规组1.7%(21/1247),调整OR 1.82(95%CI 1.06-3.13),P=0.03。
- 24小时内急性心脏事件的差异主要归因于干预组心律失常发生率增加。
- 30天内急性心脏事件:干预组6.8%(85/1249)vs 常规组6.3%(79/1247),调整OR 1.06(95%CI 0.77-1.47),P=0.71。
- 作者结论:不推荐在未经选择的择期重大胃肠手术患者中常规使用该治疗策略。
适用人群与场景
- 年龄≥65岁、美国麻醉医师协会(ASA)体能状态分级II级及以上、接受择期重大胃肠手术的成人。
- 2017年1月至2022年9月期间招募,来自全球55家医院的外科服务。
处置流程与药物剂量
- 干预组:术中和术后4小时内,采用微创心脏输出监测引导的静脉液体治疗,并联合低剂量正性肌力药输注。
- 对照组:接受常规护理,不进行心脏输出监测。
研究设计与关键结果
- 多中心随机对照试验,纳入2498例患者(平均年龄74岁,标准差6;57%为女性),干预组和常规组各1247例。
- 主要终点术后30天感染:干预组289/1247(23.2%)vs 常规组283/1247(22.7%),调整OR 1.03(95%CI 0.84-1.25),P=0.81。
- 24小时内急性心脏事件:干预组38/1250(3.0%)vs 常规组21/1247(1.7%),调整OR 1.82(95%CI 1.06-3.13),P=0.03;差异主要归因于干预组心律失常发生率增加。
- 30天内急性心脏事件:干预组85/1249(6.8%)vs 常规组79/1247(6.3%),调整OR 1.06(95%CI 0.77-1.47),P=0.71。
- 其他次要结局无差异。
证据类型、等级与局限
- 证据类型:多中心随机对照试验。
- 试验注册:ISRCTN Registry ISRCTN39653756。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者基于该试验结果认为,不推荐在未经选择的择期重大胃肠手术患者中常规使用心脏输出引导的静脉液体治疗联合低剂量正性肌力药。
- 该干预与24小时内急性心脏事件增加相关,尤其是快速性心律失常,围术期需关注心律失常监测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the clinical effectiveness and safety of a perioperative algorithm for cardiac output-guided haemodynamic therapy in patients undergoing major gastrointestinal surgery.
DESIGN: Multicentre randomised controlled trial.
SETTING: Surgical services of 55 hospitals worldwide.
PARTICIPANTS: 2498 adults aged ≥65 years with an American Society of Anesthesiologists physical status classification of II or greater and undergoing major elective gastrointestinal surgery, recruited between January 2017 and September 2022.
INTERVENTIONS: Participants were assigned to minimally invasive cardiac output-guided intravenous fluid therapy with low dose inotrope infusion during and four hours after surgery, or to usual care without cardiac output monitoring.
MAIN OUTCOME MEASURES: The primary outcome was postoperative infection within 30 days of randomisation. Safety outcomes were acute cardiac events within 24 hours and 30 days. Secondary outcomes were acute kidney injury within 30 days and mortality within 180 days.
RESULTS: In 2498 patients (mean age 74 (standard deviation 6) years, 57% women), the primary outcome occurred in 289/1247 (23.2%) intervention patients and 283/1247 (22.7%) usual care patients (adjusted odds ratio 1.03 (95% confidence interval 0.84 to 1.25); P=0.81). Acute cardiac events within 24 hours occurred in 38/1250 (3.0%) intervention patients and 21/1247 (1.7%) usual care patients (adjusted odds ratio 1.82 (1.06 to 3.13); P=0.03). This difference was primarily due to an increased incidence of arrhythmias among intervention patients. Acute cardiac events within 30 days occurred in 85/1249 (6.8%) intervention patients and 79/1247 (6.3%) usual care patients (adjusted odds ratio 1.06 (0.77 to 1.47); P=0.71). Other secondary outcomes did not differ.
CONCLUSIONS: This clinical effectiveness trial in patients undergoing major elective gastrointestinal surgery did not provide evidence that cardiac output-guided intravenous fluid therapy with low dose inotrope infusion could reduce the incidence of postoperative infections. The intervention was associated with an increased incidence of acute cardiac events within 24 hours, in particular tachyarrhythmias. Based on these findings, the routine use of this treatment approach in unselected patients is not recommended.
TRIAL REGISTRATION: ISRCTN Registry ISRCTN39653756.
参考来源
- Cardiac output-guided haemodynamic therapy for patients undergoing major gastrointestinal surgery: OPTIMISE II randomised clinical trial. BMJ. 2024. PMID: 39626899. doi:10.1136/bmj-2024-080439
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。